# YARW catalysts: Yarrow Bioscience, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/yarw/catalysts

> Yarrow Bioscience, Inc. (YARW) has 3 upcoming catalysts. The next is the YB-101 topline data readout, 2H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for YARW?

Yarrow Bioscience, Inc. (YARW) has 3 upcoming catalysts. The next is the YB-101 topline data readout, 2H 2027. Press release filed with the SEC (EX-99): "Enrollment ongoing in the Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves' disease (with or without concomitant thyroid eye disease); Phase 2a topline results expected in the second half of 2027" [Calendar and source filings](https://sec-api.dev/companies/yarw/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001566044-26-000017, https://www.sec.gov/Archives/edgar/data/1566044/000156604426000017/yarw-q32026earningsrelease.htm (retrieved 2026-11-13). Last confirmed 2026-11-12. Cite: https://sec-api.dev/companies/yarw/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Yarrow Bioscience, Inc. |
| Ticker | YARW (Nasdaq) |
| SEC CIK | 1566044 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/yarw |

## Cash runway

Cash $268.9M as of 2026-09-30; quarterly burn $90.0M; about 9.0 months of runway at that rate (XBRL company facts, accession 0001566044-26-000019).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2022 | [Repibresib trial start](https://sec-api.dev/pdufa/repibresib) | YARW | NSV in November 2022 | completed | "In November 2022, we initiated a Phase 1 clinical trial evaluating a topical formulation of repibresib first in healthy volunteers (Phase 1a) and then in subjects (Phase 1b) with nonsegmental vitiligo (NSV), an immune-mediated condition that has a high unmet need and only one approved therapy." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1566044/000162828025023740/vyne-20250331.htm)) |
| Q1 2025 | [VYN202 topline data readout](https://sec-api.dev/pdufa/vyn202) | YARW |  | scheduled | "VYN202: Expanded Phase 1b PoC study in moderate-to-severe plaque psoriasis expected to be initiated in Q1 2025, with top-line results anticipated YE 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1566044/000110465925002862/tm252956d1_ex99-1.htm)) |
| Feb 2025 | [VYN202 trial start](https://sec-api.dev/pdufa/vyn202) | YARW | moderate-to-severe plaque psoriasis | completed | "In February 2025, we initiated a Phase 1b trial of VYN202 in adult subjects with moderate-to-severe plaque psoriasis." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/vyne-20251231.htm)) |
| March 6, 2025 | [Yarrow Bioscience, Inc. earnings report](https://sec-api.dev/companies/yarw/catalysts) | YARW |  | completed | "VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1566044/000162828025010777/vyne-20250306q42024exx991.htm)) |
| mid-2025 | [Repibresib topline data readout](https://sec-api.dev/pdufa/repibresib) | YARW |  | scheduled | "•Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1566044/000162828025023478/vyne-20250508q12025exx991.htm)) |
| mid-2025 | [Yarrow Bioscience, Inc. topline data readout](https://sec-api.dev/companies/yarw/catalysts) | YARW |  | scheduled | "Top-line results from 24-week vehicle-controlled treatment period expected mid-2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1566044/000110465925002862/tm252956d1_ex99-1.htm)) |
| May 8, 2025 | [Yarrow Bioscience, Inc. earnings report](https://sec-api.dev/companies/yarw/catalysts) | YARW |  | completed | "VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1566044/000162828025023478/vyne-20250508q12025exx991.htm)) |
| August 11, 2025 | [Yarrow Bioscience, Inc. earnings report](https://sec-api.dev/companies/yarw/catalysts) | YARW |  | completed | "Inc. (Nasdaq: VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today reported financial results as of and for the quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1566044/000110465925078135/tm2523400d1_ex99-1.htm)) |
| late 2025 | [VYN202 topline data readout](https://sec-api.dev/pdufa/vyn202) | YARW | moderate-to-severe plaque psoriasis | scheduled | "We expect to enroll approximately 80 subjects with moderate-to-severe plaque psoriasis and to report top-line results from the placebo-controlled trial by the end of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1566044/000162828025010908/vyne-20241231.htm)) |
| November 6, 2025 | [Yarrow Bioscience, Inc. earnings report](https://sec-api.dev/companies/yarw/catalysts) | YARW |  | completed | "VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1566044/000156604425000007/vyne-2025116q32025exx991.htm)) |
| Mar 2026 | [YB-101 trial start](https://sec-api.dev/pdufa/yb-101) | YARW |  | completed | "In March 2026, Yarrow received IND clearance from the FDA to initiate a Phase 2 trial in GD in the United States and in June 2026, Yarrow initiated a Phase 2a/Phase 2b trial of YB-101 in patients with GD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1566044/000110465926106699/tm2624937d1_ex99-2.htm)) |
| Q2 2026 | [Thyrotropin topline data readout](https://sec-api.dev/pdufa/thyrotropin) | YARW |  | scheduled | "IND cleared for combined Phase 2a/2b GD trial; expected start in Q2 '26 with Phase 2a readout anticipated in 2H '27" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1566044/000110465926065214/tm2615387d1_ex99-1.htm)) |
| Jun 2026 | [YB-101 trial start](https://sec-api.dev/pdufa/yb-101) | YARW | GD, with or without concurrent TED | completed | "In June 2026, we initiated a combined Phase 2a/Phase 2b trial of YB-101 in patients with GD, with or without concurrent TED." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000019/yarw-20260930.htm)) |
| November 12, 2026 | [Yarrow Bioscience, Inc. earnings report](https://sec-api.dev/companies/yarw/catalysts) | YARW |  | completed | "Yarrow Bioscience Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000017/yarw-q32026earningsrelease.htm)) |
| 2H 2027 | [YB-101 topline data readout](https://sec-api.dev/pdufa/yb-101) | YARW | Graves' disease | scheduled | "Enrollment ongoing in the Phase 2a/2b trial evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves' disease (with or without concomitant thyroid eye disease); Phase 2a topline results expected in the second half of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1566044/000156604426000017/yarw-q32026earningsrelease.htm)) |
| December 2027 | [Experimental: yb-101 primary completion](https://sec-api.dev/pdufa/experimental-yb-101) | YARW | Graves' Disease | scheduled | "NCT07682896 (Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Yarrow Bioscience, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07682896)) |
| Dec 2027 to Mar 2028 | [Experimental: yb-101 topline data readout](https://sec-api.dev/pdufa/experimental-yb-101) | YARW | Graves' Disease | scheduled | "NCT07682896 (Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Yarrow Bioscience, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07682896)) |

## Drugs

- [Experimental: yb-101](https://sec-api.dev/pdufa/experimental-yb-101): Graves' Disease
- [Repibresib](https://sec-api.dev/pdufa/repibresib): nsv in november 2022
- [Thyrotropin](https://sec-api.dev/pdufa/thyrotropin): 
- [VYN202](https://sec-api.dev/pdufa/vyn202): moderate-to-severe plaque psoriasis
- [YB-101](https://sec-api.dev/pdufa/yb-101): graves' disease, gd, with or without concurrent ted

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/yarw/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "YARW catalysts: Yarrow Bioscience, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/yarw/catalysts

```bibtex
@misc{secapidev_companies_yarw_catalysts_20261116,
  title        = {YARW catalysts: Yarrow Bioscience, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/yarw/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_yarw_catalysts_20261116","title":"YARW catalysts: Yarrow Bioscience, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/yarw/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
